{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T19:39:23Z","timestamp":1787945963631,"version":"build-2784847793"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Remimazolam is a novel and ultra-short-acting sedative currently developed for intravenous use in procedural sedation, general anesthesia, and ICU sedation. However, intravenous administration is not always appropriate, depending on the patient or setting. This study evaluated intranasal administration as a potential alternative route.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study used a randomized, double-blind, 9 period cross-over design to compare the pharmacokinetics, pharmacodynamics, and safety of single intranasal doses of 10, 20, and 40\u00a0mg remimazolam (as powder or solution) with intranasal placebo and 4\u00a0mg intravenous remimazolam.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Intranasal remimazolam powder had a consistent absolute bioavailability of approximately 50%; T<jats:sub>max<\/jats:sub> was 10\u00a0min; AUC and C<jats:sub>max<\/jats:sub> were dose-proportional. The higher doses of intranasal solution, however, resulted in decreasing bioavailability and loss of dose-proportionality in AUC and C<jats:sub>max<\/jats:sub> despite complete drug absorption due to partial swallowing of dose and the resulting first-pass effect. Pharmacodynamics were generally consistent with PK. Peak effects (drowsiness, relaxation, any, memory, response time) were in similar ranges after intranasal (10 to 40\u00a0mg) as intravenous (4\u00a0mg) dosing and were partially, but not consistently, dose-related. Safety results were generally consistent with other benzodiazepines; however, intranasal remimazolam (but not placebo) caused nasal discomfort\/pain, in some cases even severe.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Intranasal administration of remimazolam was safe and caused sedative effects. However, the severe pain and discomfort caused by intranasal remimazolam prohibit its use by this route of administration, at least with the currently available intravenous formulation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-020-02984-z","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T07:02:34Z","timestamp":1599202954000},"page":"1505-1516","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Pharmacokinetics and pharmacodynamics of intranasal remimazolam\u2014a randomized controlled clinical trial"],"prefix":"10.1007","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7939-5524","authenticated-orcid":false,"given":"Marija","family":"Pesic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Schippers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyn","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Donsbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Stoehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,4]]},"reference":[{"issue":"3","key":"2984_CR1","first-page":"UE01","volume":"12","author":"S Bansal","year":"2018","unstructured":"Bansal S, Singhal SJ (2018) Remimazolam (CNS 7056): an emerging sedative and general anaesthetic. J Clin Diagn Res 12(3):UE01\u2013UE03","journal-title":"J Clin Diagn Res"},{"issue":"1","key":"2984_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.chest.2018.09.015","volume":"155","author":"NJ Pastis","year":"2019","unstructured":"Pastis NJ, Yarmus LB, Schippers F, Ostroff R, Chen A, Akulian J, Wahidi M, Shojaee S, Tanner NT, Callahan SP, Feldman G, Lorch DG Jr, Ndukwu I, Pritchett MA, Silvestri GA, PAION Investigators (2019) Safety and efficacy of remimazolam compared with placebo and midazolam for moderate sedation during bronchoscopy. Chest 155(1):137\u2013146","journal-title":"Chest"},{"issue":"4","key":"2984_CR3","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1213\/ANE.0000000000000548","volume":"120","author":"KM Borkett","year":"2015","unstructured":"Borkett KM, Riff DS, Schwartz HI, Winkle PJ, Pambianco DJ, Lees JP, Wilhelm-Ogunbiyi K (2015) A phase IIa, randomized, double-blind study of remimazolam (CNS 7056) versus midazolam for sedation in upper gastrointestinal endoscopy. Anesth Analg 120(4):771\u2013780","journal-title":"Anesth Analg"},{"issue":"1","key":"2984_CR4","first-page":"217","volume":"22","author":"C Fantacci","year":"2018","unstructured":"Fantacci C et al (2018) Intranasal drug administration for procedural sedation in children admitted to pediatric emergency room. Eur Rev Med Pharmacol Sci 22(1):217\u2013222","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"2984_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.annemergmed.2017.02.015","volume":"70","author":"MA Rech","year":"2017","unstructured":"Rech MA, Barbas B, Chaney W, Greenhalgh E, Turck C (2017) When to pick the nose: out-of-hospital and emergency department intranasal administration of medications. Ann Emerg Med 70(2):203\u2013211","journal-title":"Ann Emerg Med"},{"issue":"3","key":"2984_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40268-020-00317-0","volume":"20","author":"M Pesic","year":"2020","unstructured":"Pesic M, St\u00f6hr T, Ossig J, Borkett K, Donsbach M, Dao VA, Webster L, Schippers F (2020) Remimazolam has low oral bioavailability and no potential for misuse in drug-facilitated sexual assaults, with or without alcohol: results from two randomised clinical trials. Drugs R&D 20(3):267\u2013277","journal-title":"Drugs R&D"},{"issue":"2","key":"2984_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/BF00177553","volume":"96","author":"JM Rusted","year":"1988","unstructured":"Rusted JM, Warburton DM (1988) The effects of scopolamine on working memory in healthy young volunteers. Psychopharmacology 96(2):145\u2013152","journal-title":"Psychopharmacology"},{"issue":"Pt 3","key":"2984_CR8","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/brain\/111.3.695","volume":"111","author":"BJ Sahakian","year":"1988","unstructured":"Sahakian BJ et al (1988) A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson\u2019s disease. Brain 111(Pt 3):695\u2013718","journal-title":"Brain"},{"key":"2984_CR9","unstructured":"CDC, cantab-code.pdf"},{"issue":"2\u20133","key":"2984_CR10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.eplepsyres.2008.10.005","volume":"83","author":"DP Wermeling","year":"2009","unstructured":"Wermeling DP, Record KA, Archer SM, Rudy AC (2009) A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation. Epilepsy Res 83(2\u20133):124\u2013132","journal-title":"Epilepsy Res"},{"issue":"2","key":"2984_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.4103\/0259-1162.118954","volume":"7","author":"AA Chokshi","year":"2013","unstructured":"Chokshi AA et al (2013) Evaluation of intranasal midazolam spray as a sedative in pediatric patients for radiological imaging procedures. Anesth Essays Res 7(2):189\u2013193","journal-title":"Anesth Essays Res"},{"issue":"5","key":"2984_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/BF02021697","volume":"25","author":"HT Harcke","year":"1995","unstructured":"Harcke HT, Grissom LE, Meister MA (1995) Sedation in pediatric imaging using intranasal midazolam. Pediatr Radiol 25(5):341\u2013343","journal-title":"Pediatr Radiol"},{"issue":"12","key":"2984_CR13","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/j.1365-2044.2007.05260.x","volume":"62","author":"F Gilchrist","year":"2007","unstructured":"Gilchrist F, Cairns AM, Leitch JA (2007) The use of intranasal midazolam in the treatment of paediatric dental patients. Anaesthesia 62(12):1262\u20131265","journal-title":"Anaesthesia"},{"issue":"3","key":"2984_CR14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2344\/15-00016.1","volume":"63","author":"F Peerbhay","year":"2016","unstructured":"Peerbhay F, Elsheikhomer AM (2016) Intranasal midazolam sedation in a pediatric emergency dental clinic. Anesth Prog 63(3):122\u2013130","journal-title":"Anesth Prog"},{"issue":"2","key":"2984_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4103\/0974-2700.43189","volume":"1","author":"JR Meredith","year":"2008","unstructured":"Meredith JR, O'Keefe KP, Galwankar S (2008) Pediatric procedural sedation and analgesia. J Emerg Trauma Shock 1(2):88\u201396","journal-title":"J Emerg Trauma Shock"},{"key":"2984_CR16","unstructured":"Frans\u00e9n N Studies on a novel powder formulation for nasal drug delivery. 2008. Acta Universitatis Upsaliensis"},{"key":"2984_CR17","doi-asserted-by":"crossref","unstructured":"Marx D, Williams G, Birkhoff M (2015) Intranasal drug administration\u2014an attractive delivery route for some drugs. Drug Discov Dev:299\u2013320","DOI":"10.5772\/59468"},{"key":"2984_CR18","unstructured":"Hughes A et al. (2016) Prescription drug use and misuse in the United States: results from the 2015 National Survey on Drug Use and Health, pp A1\u2013A24"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-02984-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-020-02984-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-02984-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T01:35:40Z","timestamp":1630719340000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-020-02984-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,4]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["2984"],"URL":"https:\/\/doi.org\/10.1007\/s00228-020-02984-z","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,4]]},"assertion":[{"value":"27 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Marija Pesic, Thomas St\u00f6hr, Martin Donsbach and Frank Schippers, as current or former employees of PAION, may own stocks or stock options of PAION. Lynn Webster is an employee at PRA Early Development Services, the CRO that conducted the clinical trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}